Kala Pharmaceuticals Inc (NASDAQ:KALA) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 977,477 shares, a decrease of 27.7% from the September 28th total of 1,352,748 shares. Based on an average daily trading volume, of 854,179 shares, the days-to-cover ratio is presently 1.1 days. Currently, 4.5% of the company’s stock are sold short.
Several research analysts have weighed in on KALA shares. Zacks Investment Research cut Kala Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, August 15th. Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, August 26th. Wells Fargo & Co reissued a “buy” rating on shares of Kala Pharmaceuticals in a research report on Thursday, August 23rd. BidaskClub cut Kala Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Finally, HC Wainwright set a $35.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $28.45.
In related news, Director Gregory Grunberg purchased 606,060 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The stock was acquired at an average price of $8.25 per share, for a total transaction of $4,999,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ra Capital Healthcare Fund Lp purchased 2,424,242 shares of the firm’s stock in a transaction that occurred on Wednesday, October 3rd. The shares were bought at an average price of $8.25 per share, with a total value of $19,999,996.50. The disclosure for this purchase can be found here. Corporate insiders own 35.58% of the company’s stock.
KALA stock opened at $7.65 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 9.79 and a current ratio of 9.79. Kala Pharmaceuticals has a 1-year low of $7.53 and a 1-year high of $22.10. The firm has a market capitalization of $263.53 million, a price-to-earnings ratio of -1.31 and a beta of -1.07.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.10). As a group, research analysts predict that Kala Pharmaceuticals will post -2.25 earnings per share for the current year.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.